Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vivos Therapeutics (VVOS) Other Gross PP&E Adjustments (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 6.0% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 6.0% increase, with the full-year FY2024 number at $4.4 million, up 18.83% from a year prior.
  • Other Gross PP&E Adjustments was $5.2 million for Q3 2025 at Vivos Therapeutics, up from $4.4 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $5.2 million in Q3 2025 to a low of $1.9 million in Q1 2021.
  • A 5-year average of $3.7 million and a median of $3.7 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 139.38% in 2021, then plummeted 32.18% in 2022.
  • Vivos Therapeutics' Other Gross PP&E Adjustments stood at $2.5 million in 2021, then fell by 7.18% to $2.4 million in 2022, then surged by 57.49% to $3.7 million in 2023, then increased by 18.83% to $4.4 million in 2024, then increased by 17.43% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Gross PP&E Adjustments are $5.2 million (Q3 2025), $4.4 million (Q2 2025), and $4.7 million (Q1 2025).